Rewind Therapeutics, a private Belgian biotech company developing therapies for myelin-related diseases, has appointed Ian J. Reynolds as its CEO. Ian is a member of the Innovative Medicines Initiative Strategic Governance Group on Neurodegeneration and of the Scientific Advisory Boards of the Michael J. Fox Foundation, Target ALS and the Parkinson’s Foundation. Prior to joining Rewind Therapeutics, Ian was vice president and head of discovery research at Teva Pharmaceuticals in Pennsylvania, USA.